EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease

European Journal of Neurology

Volumn 20, Issue 1, 2013, Pages 16-34

  Berardelli, A ^a   Wenning, G K ^b   Antonini, A ^c   Berg, D ^d   Bloem, B R ^e   Bonifati, V ^f   Brooks, D ^g   Burn, D J ^h   Colosimo, C ^a   Fanciulli, A ^b   Ferreira, J ⁱ   Gasser, T ^d   Grandas, F ^j   Kanovsky, P ^k   Kostic, V ^l   Kulisevsky, J ^m   Oertel, W ⁿ   Poewe, W ^b   Reese, J P ^o   Relja, M ^p   Ruzicka, E ^q   Schrag, A ^r   Seppi, K ^b   Taba, P ^s   Vidailhet, M ^t   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c IRCCS   (Italy)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e RADBOUD UNIVERSITY   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k PALACKÝ UNIVERSITY   (Czech Republic)

^l UNIVERSITY OF BELGRADE   (Serbia)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ PHILIPPS UNIVERSITY MARBURG   (Germany)

^o Inst für Med Statistik   (Germany)

^p UNIVERSITY OF ZAGREB   (Croatia)

^q CHARLES UNIVERSITY   (Czech Republic)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF TARTU   (Estonia)

^t PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Movement disorders; Neurological disorders; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA SYNUCLEIN; APOMORPHINE; DJ 1 PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN;

ARTICLE; AUTONOMIC DYSFUNCTION; AUTOSOMAL RECESSIVE DISORDER; BLOOD FLOWMETRY; BRADYKINESIA; BRAIN ATROPHY; BRAIN BLOOD FLOW; COGNITION; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTRONYSTAGMOGRAPHY; EVOKED RESPONSE; GENE DUPLICATION; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPOSMIA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PARKINSONISM; POINT MUTATION; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REM SLEEP; RR INTERVAL; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN TEMPERATURE; SMELLING; SUBSTANTIA NIGRA; SUPERIOR CEREBELLAR PEDUNCLE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THERMOREGULATION; TREMOR; VOXEL BASED MORPHOMETRY;

AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; COGNITION DISORDERS; DATABASES, FACTUAL; DIAGNOSTIC IMAGING; EUROPE; GENETIC TESTING; GUIDELINES AS TOPIC; HUMANS; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TESTS; OLFACTION DISORDERS; PARKINSON DISEASE; RISK FACTORS; SLEEP DISORDERS;

EID: 84871664204     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12022     Document Type: Article

References (245)

1. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529-534.
2. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
3. Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS Scientific Task Forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
5. Abdo WF, van de Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol 2010; 6: 29-37.
6. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
8. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.
9. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102.
10. Jankovic J, Rajput AH, Mcdermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000; 57: 369-372.
11. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001; 57: 1687-1694.
12. Harbo HF, Finsterer J, Baets J, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 2009; 16: 777-785. Erratum in: Eur J Neurol 2010; 17: 339.
13. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009; 11: e22.
14. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173.
15. Ahn TB, Kim SY, Kim JY, et al. Alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70: 43-49.
16. Di Fonzo A, Tassorelli C, De Mari M, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006; 14: 322-331.
17. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365: 415-416.
18. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-425.
19. Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, et al. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 2006; 21: 1954-1959.
20. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
21. Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009; 66: 571-576.
22. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20: 202-210.
23. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560-1567.
24. Kay DM, Stevens CF, Hamza TH, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75: 1189-1194.
25. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003; 54: 176-185.
26. Holmberg B, Kallio M, Johnels B, Elam M. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord 2001; 16: 217-225.
27. Bordet R, Benhadjali J, Destee A, Hurtevent JF, Bourriez JL, Guieu JD. Sympathetic skin response and R-R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 1996; 11: 268-272.
28. De Marinis M, Stocchi F, Gregori B, Accornero N. Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure. Mov Disord 2000; 15: 1215-1220.
29. Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997; 62: 507-511.
30. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001; 71: 600-606.
31. Bonnet AM, Pichon J, Vidailhet M, et al. Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. Mov Disord 1997; 12: 509-513.
32. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov Disord 2000; 15: 71-76.
33. Klein C, Brown R, Wenning G, Quinn N. The "cold hands sign" in multiple system atrophy. Mov Disord 1997; 12: 514-518.
34. Pierangeli G, Provini F, Maltoni P, et al. Nocturnal body core temperature falls in Parkinson's disease but not in Multiple-System Atrophy. Mov Disord 2001; 16: 226-232.
35. Riley DE, Chelimsky TC. Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 56-60.
36. Reimann M, Schmidt C, Herting B, et al. Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 2010; 117: 69-76.
37. Hahn K, Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 2005; 20: 1499-1502.
38. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66: 742-750.
39. Pietzarka K, Reimann M, Schmidt C, et al. The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm 2010; 117: 475-479.
40. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurological signs, disease stage, or disease duration. Neurology 1988; 38: 1237-1244.
41. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 138-142.
42. Hawkes CH, Shepard BC. Olfactory dysfunction Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-446.
43. Boesveldt S, Verbaan D, Knol DL, et al. A comparative study of odour and odour discrimination deficit in Parkinson's disease. Mov Disord 2008; 23: 1984-1990.
44. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson's disease - a multicenter study. Parkinsonism Relat Disord 2008; 23: 1984-1990.
45. Muller A, Reihman H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease: results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-811.
46. Wenning GK, Shepard B, Hawkes C, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-250.
47. Berendse HW. Ponsen MM diagnosing premotor Parkinson's disease using a two-step approach combibig olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord 2009; 1583: S26-S30.
48. Katzenschlager R, Zijlmans J, Evans A, et al. Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1749-1752.
49. Lee PH, Yeo SH, Young SW, et al. Odour identification test and its relation to cardiac 123 I meta-iodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2007; 78: 1250-1252.
50. Kertelge L, Bruggemann N, Schmidt A, et al. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Mov Disord 2010; 25: 2665-2669.
51. Alcalay RN, Siderowf A, Ottman R, et al. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology 2011; 76: 319-326.
52. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173.
53. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-596.
54. Haehner A, Hummel T, Hummel C, et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007; 22: 839-842.
55. Berndse HW, Booij J, Chantal MJE, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients relatives with a decreased sense of smell. Ann Neurol 2001; 50: 34-41.
56. Iijima M, Osawa M, Momose M. Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov Disord 2010; 25: 1143-1149.
57. Ponsen MM, Sttofers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
58. Ponsen MM, Sttofers D, Twisk WR, et al. Hyposmia and executive function as predictors of future Parkinson's disease: a prospective study. Mov Disord 2009; 24: 1060-1065.
59. Ponsen MM, Sttofers D, Wolters ECh, et al. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 396-399.
60. Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y. Le test a le levodopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985; 141(Suppl.): 413-414.
61. Barker R, Duncan J, Lees AJ. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet 1989; 1: 675.
62. D'Costa DF, Abbott RJ, Pye IF, Millac PA. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991; 54: 870-872.
63. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991; 41: 1723-1725.
64. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992; 49: 1131-1134.
65. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 590-594.
66. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001; 16: 197-201.
67. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Practice. Neurology 2006; 66: 968-975.
68. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov Disord 2002; 17: 795-798.
69. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000; 43: 95-101.
70. Wenning GK, Litvan I, Verny M, et al. Is EEG useful in the differential diagnosis of parkinsonism? Parkinsonism Relat Disord 1998; 4: 79-80.
71. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer′s disease, dementia with Lewy bodies and Parkinson′s disease with dementia patients with a 2-year follow-up. Brain 2008; 131: 690-705.
72. Wang L, Kuroiwa Y, Kamitani T, et al. Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration and Parkinson′s disease. J Neurol 2000; 247: 356-363.
73. Nightingale S, Mitchell KW, Howe JW. Visual evoked cortical potentials and pattern electroretinograms in Parkinson′s disease and control subjects. J Neurol Neurosurg Psychiatry 1986; 49: 1280-1287.
74. Takeda M, Tachibana H, Okuda B, et al. Event-related potential and visual evoked potential in patients with Parkinson′s disease. Nihon Ronen Igakkai Zasshi 1993; 30: 363-368.
75. Okuda B, Tachibana H, Kawabata K, et al. Visual evoked potentials in Parkinson′s disease: correlation of pattern VEPs abnormality with dementia. Alzheimer Dis Assoc Disord 1995; 9: 68-72.
76. Rossini PM, Babiloni F, Bernardi G, et al. Abnormalities of short-latency somatosensory evoked potentials in parkinsonian patients. Electroencephalogr Clin Neurophysiol 1989; 74: 277-289.
77. Garcia PA, Aminoff MJ, Goodin DS. The frontla N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson′s disease. Neurology 1995; 45: 989-992.
78. Onofrj M, Fulgente T, Malatesta G, et al. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson′s disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations. Mov Disord 1995; 10: 71-80.
79. Bostantjopoulou S, Katsarou Z, Zafiriou D, et al. Abnormality of N30 somatosensory evoked potentials in Parkinson′s disease: a multidisciplinary approach. Neurophysiol Clin 2000; 30: 368-376.
80. Rossini PM, Basseti MA, Paqualetti P. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson′s disease and parkinsonism. Electroencephalogr Clin Neurophysiol 1995; 96: 236-247.
81. Tinazzi M, Fiaschi A, Idone D, et al. Parkinson′s disease and lower limb somatosensory evoked potentials: apomorphine-induced relief of the akinetic-rigid syndrome and vertex P37-N50 potentials. J Neurol Sci 1999; 164: 163-171.
82. Defebvre L. Extrapyramidal disorders: interest of myoclonus analysis. Rev Neurol 2007; 163: 1115-1121.
83. Van de Wassenberg WJ, van der Hoeven JH, Leenders KL. 128-Channel somatosensory evoked potentials in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord 2009; 15: 564-571.
84. Tachibana H, Takeda M, Sugita M. Short-latency somatosensory and brainstem auditory evoked potentials in patients with Parkinson′s disease. Int J Neurosci 1989; 44: 321-326 (class III study).
85. Kodama Y, Ieda T, Hirayama M, et al. Auditory brainstem responses in patients with autonomic failure with Parkinson′s disease and multiple system atrophy. J Auton Nerv Syst 1999; 77: 184-189 (class III study).
86. Laffront F, Agar N, Zuber M, et al. Auditory evoked responses (AER) and augmenting - reducing phenomenon in patients with progressive supranuclear palsy (PSP). Neurophysiol Clin 1991; 21: 149-160 (class III study).
87. Tyvaert L, Cassim F, Derambure P, Lefebvre L. Neurophysiology of corticobasal degeneration. Rev Neurol 2007; 163: 779-791 (review).
88. Cantello R, Gianelli M, Bettucci D, et al. Parkinson′s disease rigidity: magnetic motor evoked potentials in small hand muscle. Neurology 1991; 41: 1449-1456.
89. Priori A, Berardelli A, Inghilleri M, et al. Motor cortical inhibition and the dopaminergic systém. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson′s disease and drug-induced parkinsonism. Brain 1994; 117: 317-323.
90. Cantello R, Tarletti R, Civardi C. Transcranial magnetic stimulation and Parkinson′s disease. Brain Res Brain Res Rev 2002; 38: 309-327.
91. De Rosa A, Volpe G, Marcantonio L, et al. Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations. J Neurol 2006; 253: 275-279.
92. Abbruzzese G, Marchese R, Trompetto C. Sensory and motor evoked potentials in multiple system atrophy: a comparative study with Parkinson′s disease. Mov Disord 1997; 12: 315-321.
93. Wenning GK, Smith SJ. Magnetic brain stimulation in multiple system atrophy. Mov Disord 1997; 12: 452-453.
94. Morita Y, Osaki Y, Doi Y. Transcranial magnetic stimulation for differential diagnostics in patients with parkinsonism. Acta Neurol Scand 2008; 118: 159-163.
95. Vidailhet M, Rothwell JC, Thompson PD, Lees AJ, Marsden CD. The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson′s disease. Brain 1992; 115: 1181-1192.
96. Kofler M, Müller J, Wenning GK, et al. The auditory startle reaction in parkinsonian disorders. Mov Disord 2001; 16: 62-71.
97. Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997; 48: 1094-1097.
98. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622-630.
99. Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson′s disease. Mov Disord 2010; 25(Suppl. 1): S117-S122.
100. Moreno-Lopez C, Santamaria J, Salamero M, Del Sorbo F, Albanese A, et al. Excessive daytime sleepiness in jultiple system atrophy (SLEEMSA study). Arch Neurol 2011; 68: 223-230.
101. Schulte EC, Winkelmann J. When Parkinson′s disease patients go to sleep: specific sleep disturbances related to Parkinson′s disease. J Neurol 2011; 258(Suppl. 2): S328-S335.
102. Deuschl G, Krack P, Lauk M, et al. Clinical neurophysiology of tremor. J Clin Neurophysiol 1996; 13: 110-121.
103. Deuschl G. Differential diagnosis of tremor. J Neural Transm Suppl 1999; 56: 211-220.
104. Milanov I. Electromyographic differentiation of tremors. Clin Neurophysiol 2001; 112: 1626-1632.
105. Breit S, Spieker S, Schulz JB, et al. Long-term EMG recordings differentiate between parkinsonian and Essentials tremor. J Neurol 2008; 255: 103-111.
106. Eardley I, Quinn NP, Fowler CJ, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989; 64: 360-362.
107. Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler J. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 618-621.
108. Winge K, Jennum P, Lokkegaard A, et al. Anal sphincter EMG in the diagnosis of parkinsonian syndromes. Acta Neurol Scand 2010; 121: 198-203.
109. McKeith I, Dickson D, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
110. Litvan I, Bhatia KP, Burn DJ, et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003; 18: 467-486.
111. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-1069.
112. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 2008; 23: 1546-1550.
113. Aarsland D, Litvan I, Salmon D, Galakso D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1215-1220.
114. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21: 1078-1085.
115. Bak TH, Mioshi E. A cognitive bedside assessment beyond the MMSE: the Addenbrooke's Cognitive Examination. Pract Neurol 2007; 7: 245-249.
116. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009; 73: 1738-1745.
117. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
118. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003; 61: 1222-1228.
119. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23: 998-1005.
120. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009; 24: 1103-1110.
121. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-2969.
122. Dujardin K, Dubois B, Tison F, et al. Parkinson's disease dementia can be easily detected in routine clinical practice. Mov Disord 2010; 25: 2769-2776.
123. Pagonabarraga J, Kulisevsky J, Llebaria G, et al. PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease. Mov Disord 2010; 25: 440-446.
124. Stiasny-Kolster K, Mayer G, Schafer S, Carsten Moller J, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire: a new diagnostic instrument. Mov Disord 2007; 22: 2386-2393.
125. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
126. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001; 248: 684-689.
127. Walter U, Wittstock M, Benecke R, Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm 2002; 109: 191-196.
128. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM. Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. Mov Disord 2007; 22: 550-555.
129. Kim JY, Kim ST, Jeon SH, Lee WY. Midbrain transcranial sonography in Korean patients with Parkinson's disease. Mov Disord 2007; 22: 1922-1926.
130. Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007; 46: 1527-1531.
131. Ressner P, Skoloudik D, Hlustik P, Kanovsky P. Hyperechogenicity of the substantia nigra in Parkinson's disease. J Neuroimaging 2007; 17: 164-167.
132. Tsai CF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J Neurol 2007; 254: 501-507.
133. Mijajlovic M, Dragasevic N, Stefanova E, Petrovic I, Svetel M, Kostic VS. Transcranial sonography in spinocerebellar ataxia type 2. J Neurol 2008; 255: 1164-1167.
134. Budisic M, Trkanjec Z, Bosnjak J, Lovrencic-Huzjan A, Vukovic V, Demarin V. Distinguishing Parkinson's disease and essential tremor with transcranial sonography. Acta Neurol Scand 2009; 119: 17-21.
135. Berg D, Behnke S, Walter U. Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall Med 2006; 27: 12-19.
136. Walter U, Behnke S, Eyding J, et al. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 2007; 33: 15-25.
137. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008; 7: 1044-1055.
138. Skoloudik D, Walter U. Method and validity of transcranial sonography in movement disorders. Int Rev Neurobiol 2010; 90: 7-34.
139. Walter U, Kanowski M, Kaufmann J, Grossmann A, Benecke R, Niehaus L. Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: a phantom study. Neuroimage 2008; 40: 551-558.
140. van de Loo S, Walter U, Behnke S, et al. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 1087-1092.
141. Berg D. Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm 2010; 118: 453-461.
142. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson Disease. Arch Neurol 2007; 64: 1635-1640.
143. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008; 7: 417-424.
144. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004; 19: 1445-1449.
145. Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease* Brain 2005; 128: 3000-3011.
146. Hedrich K, Winkler S, Hagenah J, et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 2006; 21: 1506-1510.
147. Hagenah JM, Konig IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007; 254: 1407-1413.
148. Schweitzer KJ, Brussel T, Leitner P, et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 2007; 254: 613-616.
149. Hagenah JM, Becker B, Bruggemann N, et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 2008; 79: 1071-1074.
150. Brockmann K, Hagenah J. TCS in monogenic forms of Parkinson's disease. Int Rev Neurobiol 2010; 90: 157-164.
151. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-1031.
152. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
153. Postert T, Eyding J, Berg D, et al. Transcranial sonography in spinocerebellar ataxia type 3. J Neural Transm Suppl 2004; 68: 123-133.
154. Lambeck J, Niesen W, Zucker B. Substantia nigra hyperechogenicity in Huntington's disease. Akt Neurologie 2008; 35: 152 (abstract).
155. Krogias C, Eyding J, Postert T. Transcranial sonography in Huntington's disease. Int Rev Neurobiol 2010; 90: 237-257.
156. Krogias C, Postert T, Eyding J. Transcranial sonography in ataxia. Int Rev Neurobiol 2010; 90: 217-235.
157. Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 2005; 64: 1726-1732.
158. Walter U, Dressler D, Lindemann C, Slachevsky A, Miranda M. Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease. Mov Disord 2008; 23: 141-145.
159. Walter U. Transcranial sonography in brain disorders with trace metal accumulation. Int Rev Neurobiol 2010; 90: 166-178.
160. Walter U, Wagner S, Horowski S, Benecke R, Zettl UK. Transcranial brain sonography findings predict disease progression in multiple sclerosis. Neurology 2009; 73: 1010-1017.
161. Spiegel J, Hellwig D, Mollers MO, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006; 129: 1188-1193.
162. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005; 20: 383-385.
163. Behnke S, Double KL, Duma S, et al. Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. Neuroimage 2007; 34: 1054-1059.
164. Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010; 7: 300-318.
165. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002; 58: 575-580.
166. Ito S, Shirai W, Hattori T. Putaminal hyperintensity on T1-weighted MR imaging in patients with the Parkinson variant of multiple system atrophy. AJNR Am J Neuroradiol 2009; 30: 689-692.
167. Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002; 59: 835-842.
168. Lee EA, Cho HI, Kim SS, Lee WY. Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004; 10: 363-368.
169. Righini A, Antonini A, Ferrarini M, et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. J Comput Assist Tomogr 2002; 26: 266-271.
170. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998; 65: 65-71.
171. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697-702.
172. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999; 56: 225-228.
173. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110: 151-169.
174. Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 2002; 59: 1265-1267.
175. Savoiardo M, Strada L, Girotti F, et al. MR imaging in progressive supranuclear palsy and Shy-Drager syndrome. J Comput Assist Tomogr 1989; 13: 555-560.
176. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125: 1070-1083.
177. Ito S, Shirai W, Hattori T. Evaluating posterolateral linearization of the putaminal margin with magnetic resonance imaging to diagnose the Parkinson variant of multiple system atrophy. Mov Disord 2007; 22: 578-581.
178. Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005; 64: 675-679.
179. Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64: 2050-2055.
180. Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003; 210: 57-60.
181. Graber JJ, Staudinger R. Teaching neuroimages: "Penguin" or "hummingbird" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009; 72: e81.
182. Barsottini OG, Ferraz HB, Maia AC Jr, Silva CJ, Rocha AJ. Differentiation of Parkinson's disease and progressive supranuclear palsy with magnetic resonance imaging: the first Brazilian experience. Parkinsonism Relat Disord 2007; 13: 389-393.
183. Righini A, Antonini A, De NR, et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004; 25: 927-932.
184. Kataoka H, Tonomura Y, Taoka T, Ueno S. Signal changes of superior cerebellar peduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14: 63-65.
185. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45: 65-74.
186. Groschel K, Hauser TK, Luft A, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004; 21: 714-724.
187. Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord 2010; 25: 2444-2449.
188. Nicoletti G, Fera F, Condino F, et al. MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease. Radiology 2006; 239: 825-830.
189. Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246: 214-221.
190. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001; 58: 1076-1079.
191. Longoni G, Agosta F, Kostic VS, et al. MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord 2011; 26: 247-255.
192. Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 2004; 21: 1443-1451.
193. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922-927.
194. Seppi K, Schocke MF, Donnemiller E, et al. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Mov Disord 2004; 19: 1438-1445.
195. Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006; 21: 847-852.
196. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129: 2679-2687.
197. Kollensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771-1776.
198. Pellecchia MT, Barone P, Mollica C, et al. Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov Disord 2009; 24: 689-696.
199. Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008; 131: 2690-2700.
200. Paviour DC, Thornton JS, Lees AJ, Jager HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007; 22: 68-74.
201. Blain CR, Barker GJ, Jarosz JM, et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006; 67: 2199-2205.
202. Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Mov Disord 2008; 23: 2370-2376.
203. Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007; 78: 722-728.
204. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
205. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009; 47: 435-441.
206. Groger A, Chadzynski G, Godau J, Berg D, Klose U. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol 2011; 21: 1962-1969.
207. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133: 3423-3433.
208. Melzer TR, Watts R, MacAskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 2011; 134: 845-855.
209. Antonini A. Imaging for early differential diagnosis of parkinsonism. Lancet Neurol 2010; 9: 130-131.
210. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229-1238.
211. Benamer HTS, Patterson J, Grosset DG. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]FP-CIT SPECT imaging: the [123I]FP-CIT SPECT study group. Mov Disord 2000; 15: 503-510.
212. Vlaar AM, de Nijs T, Kessel AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258-266.
213. Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005; 128: 1605-1612.
214. 123I FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-915.
215. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007; 6: 926-932.
216. Chang CC, Liu JS, Chang YY, Chang WN, Chen SS, Lee CH. (99m)Tc-ethyl cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson's disease patients: a correlation with neuropsychological tests. Eur J Neurol 2008; 15: 61-65.
217. Feigin A, Antonini A, Fukuda M, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002; 17: 1265-1270.
218. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-897.
219. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-251.
220. Spiegel J, Möllers MO, Jost WH, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005; 20: 552-561.
221. Brooks DJ. Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol 2008; 4: 267-277.
222. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002; 43: 1324-1330.
223. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198-1212.
224. Okamura N, Villemagne V, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010; 51: 223-228.
225. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
226. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003; 48: 109-115.
227. Guttman M, Burkholder J, Kish SJ, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-1583.
228. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123 beta-CIT-FP/SPECT and Fluorine-18 FDOPA/PET. J Nucl Med 1996; 37: 1760-1765.
229. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58-64.
230. Whone AL, Watts RL, Stoessl J, et al. Slower progression of PD with ropinirol versus L-dopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
231. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009; 24: 1009-1015.
232. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128: 2777-2785.
233. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa PET study. Ann Neurol 1997; 41: 222-229.
234. Piccini P, Burn DJ, Ceravalo R, Maraganore DM, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577-582.
235. Brooks DJ, Ibañez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
236. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44: 1325-1329.
237. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-2195.
238. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and PET. Ann Neurol 1992; 31: 184-192.
239. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990; 5: 203-213.
240. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001; 57: 2083-2088.
241. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33: 518-527.
242. Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008; 23: 727-733.
243. Antonini A, Berto P, Lopatriello S, Tamma F, Annemans L, Chambers M. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord 2008; 23: 2202-2209.
244. Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borght T. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367-1376.
245. Dodel RC, Höffken H, Möller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord 2003; 18(Suppl. 7): S52-S62.